Tin tức & Cập nhật

Venetoclax + chemo disappoints in double-hit lymphoma trial
Venetoclax + chemo disappoints in double-hit lymphoma trial
27 Dec 2021 bởiAudrey Abella

In patients with double-hit lymphoma (DHL), the addition of the BCL2 inhibitor venetoclax to a chemoimmunotherapeutic regimen comprising DA-EPOCH-R* led to excess treatment-related mortality compared with DA-EPOCH-R alone, according to the initial results of the phase II/III Alliance A051701 trial.

Venetoclax + chemo disappoints in double-hit lymphoma trial
27 Dec 2021
Lumateperone improves depression symptoms in bipolar disorder
Lumateperone improves depression symptoms in bipolar disorder
26 Dec 2021

Treatment with 42-mg lumateperone daily leads to significant improvement in depression symptoms, with no serious safety issues, among patients with major depressive episodes associated with both bipolar I and II disorders, a study has shown.

Lumateperone improves depression symptoms in bipolar disorder
26 Dec 2021
Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
25 Dec 2021

For older acute coronary syndrome (ACS) patients with implanted bioabsorbable polymer sirolimus-eluting stents, a strategy involving ticagrelor monotherapy after 3‐month dual antiplatelet therapy (DAPT) is better than ticagrelor‐based 12‐month DAPT, according to a post hoc analysis of the TICO* trial. Furthermore, the beneficial effect of ticagrelor monotherapy increases with age and is strongest among patients aged ≥64 years.

Ticagrelor monotherapy following short-term DAPT more suitable for seniors with ACS
25 Dec 2021